Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly

International Journal of Cardiology

Volumn 155, Issue 1, 2012, Pages 160-166

  Gelbrich, Götz ^a   Edelmann, Frank ^b   Inkrot, Simone ^c   Lainscak, Mitja ^c,d   Apostolovic, Svetlana ^e   Neskovic, Aleksandar N ^f   Waagstein, Finn ^g   Loeffler, Markus ^a   Anker, Stefan D ^d,h   Dietz, Rainer ^c   Düngen, Hans Dirk ^c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d University Hospital Golnik   (Slovenia)

^e University Clinical Centre Nis   (Serbia)

^f UNIVERSITY OF BELGRADE   (Serbia)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Beta blocker; Elderly patients; Guidelines; Heart failure; Heart rate; Target dose

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL;

ADL DISABILITY; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE FLUCTUATION; BRADYCARDIA; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG TOLERANCE; DYSPNEA; EXERCISE TEST; FEMALE; HEART FAILURE; HEART RATE VARIABILITY; HUMAN; HYPOTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SELF EVALUATION; SIX MINUTE WALK DISTANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VERTIGO;

EID: 84859908865     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.11.018     Document Type: Article

References (18)

1. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89. Errata in Eur J Heart Fail 2009;11:110. Eur J Heart Fail 2010;12:416.
2. Calvert MJ, Shankar A, McManus RJ, Ryan R, Freemantle N. Evaluation of the management of heart failure in primary care. Fam Pract 2009;26:145-53.
3. Komajda M, Follath F, Swedberg K, et al. The Euroheart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe: part 2: treatment. Eur Heart J 2003;24:464-74.
4. Dini L, Heintze C, Welke J, Stein T, Rufer V, Braun V. Are there any differences in guideline adherence to pharmacotherapy of heart failure between individual GP practices and Medical Care Centres (MCCs)? Z Evid Fortbild Qual Gesundhwes 2010;104:113-9 [German].
5. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010;122:585-96.
6. Steinman MA, Harlow JB, Massie BM, Kaboli PJ, Fung KZ, Heidenreich PA. Age and receipt of guideline-recommended medications for heart failure: a nationwide study of veterans. J Gen Intern Med 2011;26:1152-9.
7. Angermann CE, Gelbrich G, Störk S, et al. Somatic correlates of comorbid major depression in patients with systolic heart failure. Int J Cardiol 2011;147:66-73.
8. Düngen HD, Apostolović S, Inkrot S, et al. Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol 2008;97:578-86.
9. Düngen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 2011;13:670-80.
10. Lainscak M, Moullet C, Schön N, Tendera M. Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. Int J Cardiol 2007;122:149-55.
11. Ware JE, Sherbourne CD. 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
12. Lainscak M, Farkas J, Inkrot S, et al. Self-rated health predicts adverse events during beta-blocker treatment: the CIBIS-ELD randomised trial analysis. Int J Cardiol Jun 6 2011, doi:10.1016/j.ijcard.2011.05.037 [Epub ahead of print].
13. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784-94.
14. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886-94.
15. Arad M, Adler Y, Koren-Morag N, et al. Exercise training in advanced heart failure patients: discordance between improved exercise tolerance and unchanged NTproBNP levels. Int J Cardiol 2008;126:114-9.
16. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85. Erratum in Lancet 2010;376:1988.
17. Volterrani M, Cice G, Caminiti G, et al. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). Int J Cardiol 2011;151:218-24.
18. Shewan LG, Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.